Home › High Blood Pressure › NCT06150560

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* B/S1 hypertension
* SBP 100-139 average based on 3 office measurements.
* Age 18 or Older
* Previous COA Repair

Exclusion Criteria:

* Currently on beta blocker (BB) therapy
* Pregnancy/lactating
* eGFR\<30
* Hyperkalemia (serum potassium \>5.5mmol/L)
* Severe Aortic or Mitral valve stenosis or regurgitation
* Epicardial CAD diagnosis
* Received antihypertensive medications within the past year

About the study

The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.

What is being tested

• Losartan (drug)
• Amlodipine (drug)
• Placebo (drug)

Sponsor: Mayo Clinic · Participants: 120 · Started: Apr 1, 2024

Contact the study team

• ACHD Research Program · Phone: (507) 293-2565
• Alexander Egbe, MBBS, MPH · Phone: (507) 284-2520

Official record on ClinicalTrials.gov — NCT06150560

Locations in the U.S.

Conditions

• High Blood Pressure

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.